A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
ConditionAlopecia Areata
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-50
SponsorEli Lilly and Company
About this trial
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study drug will be administered intravenously (IV) (into a vein in the arm).
The study will last approximately 48 weeks, including screening.
Eligibility criteria
Qualifiers
Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
Agree not to use any AA treatments during the study
Disqualifiers
Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
Are currently experiencing other forms of alopecia
Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
Have received oral JAK Inhibitors in the past
Trial design
Treatments tested in this trial
- LY4005130
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
30Canada
Kelowna Health and Memory CentreV1Y 5A8, Kelowna Canada
Ryan Clinical Research Inc.L3Y 5G8, Newmarket Canada
Dar Clinical Research - Ottawa - Hunt Club RoadK1V 1C1, Ottawa Canada
SIMa RechercheH4G 2L8, Verdun Canada
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov